Connect to other sites within the UBM Medica Network
Opdivo and Yervoy may cause inflammatory arthritis and sicca syndrome among some patients. Image © blackboard1965/Shutterstock.com
ROCKET Trial Reopened Following FDA Review of Cerebral Edema Mortality
Juno Therapeutics has reopened the phase II clinical trial (ROCKET trial) of JCAR015 in adult patients with B-cell acute lymphoblastic leukemia following three deaths.
PD-L1 Testing Improves Nivolumab’s Cost-Effectiveness for Metastatic Nonsquamous Lung Cancers
Prescribing nivolumab only to patients with programmed cell death ligand 1-positive (PD-L1+) tumors improves its cost-effectiveness.
Brigatinib Trial Taking Place for ALK-Positive NSCLC Patients
Virginia Cancer Specialists reported they have enrolled the first patient in a new advanced lung cancer clinical trial for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
Blood Biomarker Detects Residual Disease, Recurrence Risk in Colon Cancer
Circulating tumor DNA detected after resection of stage II colon cancer appears to identify patients who are at high-risk of tumor recurrence.
Response With Neratinib Against Early HER2-Positive, HR-Negative Breast Cancer
Adding neratinib to standard paclitaxel chemotherapy appears to be associated with a better pathological complete response rate than chemotherapy plus trastuzumab.
To Treat or Not to Treat DCIS
Researchers from the University of Michigan have developed new technology to separate aggressive stage 0 breast cancer from nonaggressive forms.
Triptolide May Benefit Some Patients With Pancreatic Cancer
Researchers are reporting they have identified ERCC3 as a new target for pancreatic cancer and demonstrated the effects are extremely strong in a molecularly defined subset of patients.
Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma
In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
ASCO 2016: Phase I Trial Results With Vorinostat in Head and Neck Cancer
In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
March 2016 News Recap
In case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side Effects
This slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Slide Show: Highlights From the 2015 ASCO Breast Cancer Symposium
This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.
Slide Show: Trends in Targeted Therapies and Immunotherapies
This slide show provides information on the present and future of targeted therapies and immunotherapies based on a report from the IMS Institute for Healthcare Informatics.
By clicking Accept, you agree to become a member of the UBM Medica Community.